



**СРПСКИ АРХИВ**  
ЗА ЦЕЛОКУПНО ЛЕКАРСТВО  
**SERBIAN ARCHIVES**  
OF MEDICINE

Address: 1 Kraljice Natalije Street, Belgrade 11000, Serbia

+381 11 4092 776, Fax: +381 11 3348 653

E-mail: [office@srpskiarhiv.rs](mailto:office@srpskiarhiv.rs), Web address: [www.srpskiarhiv.rs](http://www.srpskiarhiv.rs)

**Paper Accepted\***

**ISSN Online 2406-0895**

**Case report / Приказ болесника**

Igor Vasković<sup>1,\*</sup>, Ivo Udovičić<sup>1</sup>, Mihailo Stojić<sup>1</sup>, Ljiljana Arsenović<sup>2</sup>, Vojislava Nešković<sup>1</sup>

**Retroperitoneal hematoma: an unexpected complication of anticoagulant therapy in COVID-19 patients**

Ретроперитонеални хематом – неуобичајена компликација антикоагулантне терапије код болесника са ковидом 19

<sup>1</sup>Military Medical Academy, Clinic for Anesthesiology and Intensive Care, Belgrade, Serbia;

<sup>2</sup>Military Medical Academy, Institute for Medical Biochemistry, Belgrade, Serbia

**Received: August 24, 2022**

**Revised: February 13, 2023**

**Accepted: February 14, 2023**

**Online First: March 3, 2023**

**DOI: <https://doi.org/10.2298/SARH220824023V>**

\***Accepted papers** are articles in press that have gone through due peer review process and have been accepted for publication by the Editorial Board of the *Serbian Archives of Medicine*. They have not yet been copy-edited and/or formatted in the publication house style, and the text may be changed before the final publication.

Although accepted papers do not yet have all the accompanying bibliographic details available, they can already be cited using the year of online publication and the DOI, as follows: the author's last name and initial of the first name, article title, journal title, online first publication month and year, and the DOI; e.g.: Petrović P, Jovanović J. The title of the article. Srp Arh Celok Lek. Online First, February 2017.

When the final article is assigned to volumes/issues of the journal, the Article in Press version will be removed and the final version will appear in the associated published volumes/issues of the journal. The date the article was made available online first will be carried over.

**\*Correspondence to:**

Igor VASKOVIĆ

Military Medical Academy, Clinic for Anesthesiology and Intensive Care  
Crnotravska 17, 11000 Belgrade, Serbia

[vaske79@gmail.com](mailto:vaske79@gmail.com)

## Retroperitoneal hematoma: an unexpected complication of anticoagulant therapy in COVID-19 patients

Ретроперитонеални хематом – неуобичајена компликација антикоагулантне терапије код болесника са ковидом 19

### SUMMARY

**Introduction** Coronavirus disease 2019 (COVID-19) is associated with high inflammatory response, hemostatic disturbances, and high thrombotic risk. Despite thromboprophylaxis, a high incidence of thromboembolic events has been reported with a consequent increase in anticoagulant therapy from standard to intermediate or even therapeutic doses. However, published evidence on the incidence and outcome of the hemorrhagic complications of applied therapy is still limited.

**Case report** We present two female COVID-19 patients, treated with anticoagulant therapy and suffering from major spontaneous bleeding and retroperitoneal hematoma. The first, 64-year-old patient, treated with non-invasive ventilation protocol in the Intensive Care Unit (ICU) due to respiratory failure received a therapeutic dose of anticoagulant therapy adjusted to the anti-Xa assay. The cumulative dose of Nadroparin was 150 IU/kg BW/day. The second, 60-year-old patient with the moderate clinical presentation on low flow oxygen support was treated with therapeutic doses of anticoagulant therapy calculated according to the body weight. Emergency open surgery was performed due to massive bleeding. No active surgical bleeding was detected, and retroperitoneal hematomas were assumed to be complications of the applied anticoagulant therapy. Both patients were discharged and fully recovered.

**Conclusion** Although rare, severe hemorrhage requires attention when considering anticoagulant therapy in COVID-19. Uncommon sites of spontaneous bleeding suggest additional evaluation on a case-by-case basis, given that a diagnosis is often delayed due to a lack of specific presenting symptoms. Further studies are needed to verify the risk-benefit ratio of different regimens of anticoagulant therapy in patients with COVID-19.

**Keywords:** COVID-19; anticoagulants; hemorrhage; retroperitoneal space

### САЖЕТАК

**Увод** Коронавирусна болест 2019 (ковид 19) се карактерише хиперинфламаторним одговором, хемостатским поремећајима и високим ризиком од тромбозе. Упркос тромбопрофилакти, бројне студије су показале високу инциденцију тромбоемболијских догађаја са последичним повећањем дозе антикоагулантне терапије од стандардних, до интермедијерних или чак терапијских. Међутим, објављени подаци о учесталости и исходу хеморагијских компликација примењених протокола лечења су и даље ограничени.

**Приказ болесника** У тексту се приказују две болеснице са ковидом 19 и појавом масивног крварења (спонтани ретроперитонеални хематом) као последицом примењене антикоагулантне терапије. Прва, 64-годишња болесница, примљена је у Јединицу интензивног лечења због тешке респираторне инсуфицијенције. Започета је неинвазивна механичка вентилација и терапијска доза антикоагулантне терапије одређена вредностима анти-Ха теста. Кумулативна доза Надропарина је била 150 IU/kg ТМ. Код друге 60-годишње болеснице са билатералном пнеумонијом и умерено тешком клиничком сликом примењене су терапијске дозе антикоагулантне терапије израчунате према телесној тежини. Обе болеснице су пребачене у другу установу и подвргнуте хитној хируршкој интервенцији због значајног крварења.

Активно хируршко крварење није откривено, а ретроперитонеални хематоми се сматрају компликацијом примењене терапије. Обе болеснице су отпуштене са лечења у добром општем стању.

**Закључак** Масивно крварење представљају ретку, али могућу компликацију антикоагулантне терапије код болесника са ковидом 19. Неуобичајена места спонтаног крварења захтевају индивидуални терапијски приступ болеснику, с обзиром да се дијагноза често одлаже због недостатка специфичних симптома. Потребне су даље студије да би се испитала ефикасност и безбедност примене различитих протокола антикоагулантне терапије, посебно виших терапијских доза, код болесника са ковидом 19.

**Кључне речи:** ковид 19; антикоагулантна терапија; крварење; ретроперитонеум

## INTRODUCTION

Coronavirus disease 2019 (COVID-19) is a systemic disease characterized by immune system hyperactivity, endothelial dysfunction, and hemostasis disorders. Hemostasis disorders are one of the critical aspects of the pathophysiology of this disease, and various mechanisms such as cytokine storm, antiphospholipid syndrome, activation of macrophages and complement cascades are related to them [1]. All these derangements significantly increase the risk of thrombosis, and 20–30% of COVID-19 critically ill patients develop pulmonary thromboembolism and deep vein thrombosis [2]. On the other hand, studies published before the pandemic showed that 8–10% of patients in ICU develop thromboembolic complications regardless of prophylactic doses of anticoagulant therapy [3].

The high incidence of thrombosis in patients with COVID-19 made some clinicians increase the dose of anticoagulant therapy from prophylactic to intermediate or therapeutic doses. However, the efficacy and safety of various anticoagulant therapy protocols are still lacking [4]. Most of the published clinical trials have focused on thromboembolic complications, while the risk factors and frequency of bleeding, and its impact on patient morbidity and mortality, remain unknown.

Here we present two female COVID-19 patients, treated with anticoagulant therapy and suffering from major spontaneous bleeding and retroperitoneal hematoma. Our research database covered the period from April 2020 to December 2021 in Covid hospital Karaburma.

## CASE REPORT

### Case 1

A 60-year-old woman, a long-term hypertensive patient on regular therapy, obese (BW 90kg, BH 175cm), and unvaccinated, was transferred from the ward of our hospital to the Intensive Care Unit (ICU) due to respiratory insufficiency. At the time of her deterioration, she

had oxygen support with a non-rebreather mask (NRM) with a flow rate of 15 l/min. She was dyspnoeic, with paroxysmal coughing fits, tachypneic with a respiratory rate up to 35/min, with oxygen saturation (SpO<sub>2</sub>) of 89–92%. Immediately after admission, non-invasive ventilation (NIV) was started, with the following parameters: FiO<sub>2</sub> 80%, PEEP 8 cmH<sub>2</sub>O, Pasp 0, whereby the respiratory frequency decreased to 25/min with SpO<sub>2</sub> of 96–97%. Her initial X-rays showed bilateral patchy pulmonary infiltrates. (Figure 1) Twelve hours after admission, and after measurement of arterial blood gas test (pH 7.46, PaCO<sub>2</sub> 33 mmHg, PaO<sub>2</sub> 170 mmHg, HCO<sub>3</sub><sup>-</sup> 23.5 mmol/l, BE 0.2 mmol/l, lactate 1.0 mmol/l), respiratory parameters were corrected to FiO<sub>2</sub> 60%, PEEP 6 cmH<sub>2</sub>O, Pasp 0.

Low Molecular Weight Heparin (LMWH) was dosed according to the local algorithm of the hospital: Nadroparin 0.6 ml subcutaneously (SQ), once a day for patients up to 100 kg or 0.9 ml subcutaneously, once a day for patients over 100 kg, if the D-dimer values were < 2 mg /L Fibrinogen Equivalent Units (FEU); while for patients with D-dimer >2 mg/L FEU, an adequate dose (relative to body weight) of LMWH was given twice a day. Thus, an initial intermediate dose of anticoagulant therapy was started with Nadroparin 0.6 ml, (SQ), twice daily. After four doses of nadroparin, on the third day and four hours after the morning dose, an anti-Xa test was performed together with other hemostasis parameters. (Table 1) After obtaining the anti-Xa test (0.5 U/ml), anticoagulant therapy was corrected (Nadroparin 0.6ml + 0.9ml) so that the cumulative dose of 150 U/kg BW/day was reached. After dose adjustment, according to the same regimen, the patient's hemostatic profile was repeated on the eighth day when the anti-Xa test value was assumed satisfactory (1.07 U/ml). (Table 1)

On the third day, after checking the blood investigation, Tocilizumab was prescribed according to the drug administration protocol due to further deterioration. (Table 1)

In the next few days, the patient improved, and the values of the inflammatory parameters decreased. (Table 1) On the tenth day, her oxygen support switched from NIV to a non-

rebreather mask, with a gradual reduction in oxygen flow over the next few days.

On the fifteenth day, the patient complained of lower abdominal pain in the morning. In the afternoon, the pain became more intense with abdominal tenderness and minimal distention. She became hypotensive and tachycardic. The laboratory tests revealed a decrease in hemoglobin level to 108 mg/l (Table 1). She had oxygen support with NRM 15L/min, and arterial blood gas test showed PaO<sub>2</sub> 192 mmHg, PaCO<sub>2</sub> 31mmHg, HCO<sub>3</sub> 23.1, BE 0.2, lactates 3.1.

Due to the hospital's limited resources, the patient was transferred to another hospital for further diagnosis and treatment under suspicion of severe bleeding. The patient underwent an urgent medial laparotomy with the dominant finding of the right rectus abdominis muscle's hematoma and bilateral retroperitoneal bleeding. Approximately 1300 ml of blood with coagula were evacuated. (Figure 2) The postoperative course was uneventful, and the patient was discharged from the hospital in a good general condition.

## Case 2

A sixty-three-year-old obese woman (BW 70kg, BH 157cm), vaccinated, with rheumatoid arthritis, after the triage in the Covid center in Belgrade, was admitted to the ward of our hospital for further treatment of proven SARS-CoV-2 infection and consequential bilateral pneumonia. The disease began ten days before admission with the appearance of cough, malaise, shortness of breath, and fever. Immediately after admission, supportive oxygen therapy was initiated using a nasal catheter (NC) with a flow rate of 2 l/min, achieving SpO<sub>2</sub> of 96-97%. The initial chest X-ray showed extensive bilateral pulmonary infiltrates involving both lower lobes with a zone of reduced paracardially transparency of the left lung (Figure 3).

Prophylactic thromboprophylaxis was started with Nadroparin 0.6 ml, SQ, once daily according to the local algorithm. In the next few days, the patient's condition worsened with a

progressive increase in oxygen support. After checking laboratory results on the fifth hospital day, Tocilizumab was prescribed according to the drug dosage information (Table 2). On the eighth day, due to further progression of the disease, oxygen support was increased to NRM with a flow rate of 15 l/min. The therapeutic dose of anticoagulant therapy was started according to the patient body weight, with nadroparin 0.6 ml twice a day.

In the next few days, the patient improved with a decrease in inflammatory parameters (Table 2) and a gradual decrease of oxygen support to the nasal catheter at a flow rate of 2 l/min.

Sixteen days after admission, the patient complains of abdominal pain. The abdomen was painfully sensitive to light and deep palpation during the physical examination, particularly in the ileocecal and suprapubic regions. Urine retention was assumed, but 100 ml of clear urine was obtained after the urinary catheter placement. The laboratory tests revealed a slight decrease in hemoglobin level compared to the previous result, but still within the normal range (Table 2). The patient became hypotensive and tachycardic, and because of suspicion of acute abdomen and bleeding as a complication of anticoagulant therapy, she was urgently transported to the surgical facility of another Covid hospital.

Abdominal and pelvic CT scans showed hematomas of rectus abdominis muscles,  $42 \times 56 \times 110$  mm on the left and  $40 \times 55 \times 120$  mm on the right side. There were also two hemorrhagic collections: in the right pelvis with a diameter of  $60 \times 90$  mm, which pushes the central pelvic organs contralaterally, and in the right retroperitoneum with a size of  $80 \times 110$  mm, which luxates the ascending colon and pushes the right kidney to the anterior abdominal wall. (Figure 4) The patient underwent emergency surgery when around 3000 ml of blood with coagula was evacuated. The postoperative course went well, and the patient was discharged from the hospital in a good general condition.

Data from the database of the doctoral dissertation "Hemostatic profile and effectiveness of anticoagulant therapy in patients with acute respiratory failure in Covid-19" was used, which was approved by the Ethics Committee of the Military Medical Academy on May 25, 2022.

## DISCUSSION

All anticoagulation guidelines in COVID-19 suggest thromboprophylaxis for hospitalized patients [5]. Three large international clinical trials published last year, collectively called multiplatform randomized controlled trials, described the effects of different dose regimens of heparin in both non-critically and critically ill patients [6, 7]. The primary outcome was a combination of hospital mortality and organ support-free days at 21 days in non-critically ill patients or patients in the ICU (critically ill). The results showed that therapeutic anticoagulation did not improve outcomes or mortality in the critically ill (including patients receiving high-flow oxygen). Opposite to this, in patients with moderate COVID-19 and low flow oxygen support, therapeutic anticoagulation reduced the need for organ support. Although low, the incidence of bleeding was higher with therapeutic anticoagulation than with usual thromboprophylaxis in both groups of patients [6, 7]. In ICU patients, major bleeding occurred in 3.8% of the patients assigned to receive therapeutic-dose anticoagulation and 2.3% of those assigned to receive usual-care thromboprophylaxis [6]. In non-critically ill patients, major bleeding occurred in 22 of 1180 patients (1.9%) in the therapeutic-dose anticoagulation group and 9 of 1047 (0.9%) in the usual-care thromboprophylaxis group. Fatal bleeding occurred in three patients in the anticoagulation group and one in the thromboprophylaxis group [7]. Our first patient was critically ill with high flow oxygen support and a therapeutic dose of anticoagulant therapy adjusted to anti-Xa assay; the second was moderately ill on low flow oxygen and therapeutic doses of anticoagulation calculated according to the body weight. Although current guidelines recommend a prophylactic anticoagulation for adults who require

ICU-level care, including those receiving high-flow oxygen, and a therapeutic dose of anticoagulation for patients who require low-flow oxygen, both of our patients had significant bleeding as a complication of therapeutic anticoagulation therapy [8]. Moreover, they had a spontaneous retroperitoneal hematoma (SRH), an unusual and uncommon complication of anticoagulants [9].

SRH is challenging to diagnose because of the vague signs and symptoms. Patients with retroperitoneal bleeding have very subtle clinical signs of hemorrhage. Very discreet hemodynamic instability, mild hypotension and tachycardia that improve with intravenous fluids for a short period should raise the clinician's suspicion about possible retroperitoneal hematoma and further investigation [10]. It is believed that the term spontaneous means the absence of specific underlying pathology or trauma; many data implied that unrecognized, minor injuries such as vomiting or coughing can cause minor bleeding that can be promoted and augmented with anticoagulation therapy. In a small study with 12 patients, anticoagulation therapy was the reason for large hematoma of the rectus abdominis muscle; six of them had a history of coughing attacks [11]. This may be a plausible explanation of our patients' rectus abdominis muscle hematomas and retroperitoneal bleeding mechanism, considering the low bleeding risk of our patients in view of the lack of other comorbidities such as renal disease or any bleeding disorders.

SRH is usually associated with anticoagulant therapy, bleeding disorders, and hemodialysis patients [12]. Recently, spontaneous retroperitoneal bleeding with massive deep vein thrombosis has been reported in a patient with COVID-19 who was not even on anticoagulant therapy, without any history of bleeding diathesis or trauma prior to admission to the hospital [13]. This case emphasizes that the COVID-19 induced procoagulant state can cause massive thrombosis and the need for therapeutic doses of anticoagulation. However, the risk of hemorrhagic complications should always be considered, with caution regarding dose

regimens of anticoagulant therapy in specific patients.

It is very delicate to keep the equilibrium between anticoagulant therapy, and thrombotic and hemorrhagic complications in patients with COVID-19. Hence, the optimal anticoagulation protocol is still debatable. Retroperitoneal hematoma, an uncommon site of spontaneous bleeding, is a rare complication of anticoagulants. Additional evaluation on a case-by-case basis is needed in light of the absence of specific presenting symptoms and delayed diagnosis. Further studies are needed to verify the risk-benefit ratio of different regimens of anticoagulant therapy in patients with COVID-19.

## ACKNOWLEDGMENT

The article was presented at the Congress "Fighting COVID-19 Pandemic - Health Challenges

COLLECTIVE KNOWLEDGE. GLOBAL HEALTH" in Belgrade, 26-28 March 2022. and the abstract was published in Proceedings.

Data from the database of the doctoral dissertation "Hemostatic profile and effectiveness of anticoagulant therapy in patients with acute respiratory failure in Covid-19" was used.

**Conflict of interest:** None declared.

## REFERENCES

1. Shi K, Liu Y, Zhang Q, Ran CP, Hou J, Zhang Y, et al. Severe Type of COVID-19: Pathogenesis, Warning Indicators and Treatment. *Chin J Integr Med*. 2022 Jan;28(1):3-11. doi: 10.1007/s11655-021-3313-x. PubMed PMID: 34962616; PubMed Central PMCID: PMC8713541.
2. Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. *J Thromb Haemost*. 2020 Aug;18(8):1995-2002. doi: 10.1111/jth.14888. PubMed PMID: 32369666; PubMed Central PMCID: PMC7497052.
3. Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCT, Fogerty AE, Waheed A, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. *Blood*. 2020 Jul 23;136(4):489-500. doi: 10.1182/blood.202006520. PubMed PMID: 32492712; PubMed Central PMCID: PMC7378457.
4. Parks AL, Auerbach AD, Schnipper JL, Anstey JE, Sterken DG, Hecht TEH, et al. Hospital Medicine Reengineering Network (HOMERuN). COVID-19 coagulopathy and thrombosis: Analysis of hospital protocols in response to the rapidly evolving pandemic. *Thromb Res*. 2020 Dec;196:355-358. doi: 10.1016/j.thromres.2020.09.018. PubMed PMID: 32977136; PubMed Central PMCID: PMC7492800.
5. Kyriakoulis KG, Kollias A, Kyriakoulis IG, Kyprianou IA, Papachrysostomou C, Makaronis P, et al. Thromboprophylaxis in Patients with COVID-19: Systematic Review of National and International Clinical Guidance Reports. *Curr Vasc Pharmacol*. 2022;20(1):96-110. doi: 10.2174/157016119666210824160332. PubMed PMID: 34431465.
6. Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. *N Engl J Med*. 2021 Aug 26;385(9):777-789. doi: 10.1056/NEJMoa2103417. PubMed PMID: 34351722; PubMed Central PMCID: PMC8362592.
7. Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN et al.. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. *N Engl J Med*. 2021 Aug 26;385(9):790-802. doi: 10.1056/NEJMoa2105911. PubMed PMID: 34351721; PubMed Central PMCID: PMC8362594.
8. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at <https://www.covid19treatmentguidelines.nih.gov/> Accessed August 12th, 2022
9. Daliakopoulos SI. Spontaneous retroperitoneal hematoma: a rare devastating clinical entity of a pleiada of less common origins. *J Surg Tech Case Rep*. 2011 Jan;3(1):8-9. doi: 10.4103/2006-8808.78462. PubMed PMID: 22022645; PubMed Central PMCID: PMC3192510.
10. Money SR, Lepore MR. Iatrogenic vascular trauma. In: Rich NM, Mattox KL, Hirshberg A, editors. *Vascular Trauma*, 2nd ed. Philadelphia, PA: Elsevier Saunders Publishers; 2004. P. 427-42.
11. Berná JD, Zuazu I, Madrigal M, García-Medina V, Fernández C, Guirado F. Conservative treatment of large rectus sheath hematoma in patients undergoing anticoagulant therapy. *Abdom Imaging*. 2000 May-Jun;25(3):230-4. doi: 10.1007/s002610000007. Pub Med PMID: 10823439.
12. Daliakopoulos SI, Bairaktaris A, Papadimitriou D, Pappas P. Gigantic retroperitoneal hematoma as a complication of anticoagulation therapy with heparin in therapeutic doses: a case report. *J Med Case Rep*. 2008 May 17;2:162. doi: 10.1186/1752-1947-2-162. Pub Med PMID: 18485233; Pub Med Central PMCID: PMC2412892.
13. Erdinc B, Raina JS. Spontaneous Retroperitoneal Bleed Coincided With Massive Acute Deep Vein Thrombosis as Initial Presentation of COVID-19. *Cureus*. 2020 Aug 15;12(8):e9772. doi: 10.7759/cureus.9772. PubMed PMID: 32953290; PubMed Central PMCID: PMC7491698.

**Table 1.** Case 1 – blood tests during the intensive care unit course

Data	Hgb g/l	Plt 10 <sup>9</sup> /l	Urea mmol/l	Cre mmol/l	GFR ml/min/1.73 m <sup>2</sup>	CRP mg/l	IL6 pg/ml	INR	Fib g/l	Dd mg/l	AT III U/ml	Axa U/ml
Normal range	115–165	140–450	2.5–7.5	44–88	≥ 90	0–5		0.7–1.2	2–4	0–0.5	0.8–1.2	
Day 1	137	246	9.1	56	101	18.1	19.6	0.92		2.13		
Day 3	125	291	9.0	44	107	169.3	576	1.04	6.2	3.02	0.94	0.50
Day 5	129	252	7.1	47	106	61.4			4.9	3.80		
Day 7	143	394	6.3	50	104	8.7				6.38		
Day 8								1.01	2.5	3.71	0.85	1.07
Day 11	134	342	6.1	45	107	2.1				1.69		
Day 14	135	251	6.2	49	105	0.7				0.91		
Day 15	108	259	8.5	44	107	0.5		1.07		0.64		

Hgb – hemoglobin; Plt – platelets; Cre – creatinine; GFR – glomerular filtration rate; CRP – C-reactive protein;

IL6 – interleukin 6; Fib – fibrinogen; Dd – D dimer; AT III – antithrombin III; AXa – anti Xa assay

(Therapeutic range 0.5–1 U/ml, prophylaxis range 0.1–0.4 U/ml)

**Table 2.** Case 2 – blood tests during the hospital course


Data	Hgb (g/l)	Plt 10 <sup>9</sup> /l	Urea (mmol/l)	Cre (mmol/l)	GFR ml/min/1.73 m <sup>2</sup>	CRP (mg/l)	IL6 (pg/ml)	INR	Dd (mg/l)
<b>Normal range</b>	115–165	140–450	2.5–7.5	44–88	≥ 90	0–5			0–0.5
<b>Day 1</b>	144	162	5.0	66	90	18.1			0.41
<b>Day 2</b>	133	293	7.5	61	97	74.3	75.4		0.52
<b>Day 6</b>	134	337	6.6	56	99	73.0			0.73
<b>Day 8</b>	145	493	8.9	63	95	18.8			1.86
<b>Day 13</b>	136	362	8.5	53	101	1.2			0.83
<b>Day 16</b>	130	304	7.1	54	100	0.4		0.97	0.65

Hgb – hemoglobin; Plt – platelets; Cre – creatinine; GFR – glomerular filtration rate; CRP – C-reactive protein;

IL6 – interleukin 6; Dd – D dimer




**Figure 1.** Case 1 - Chest radiograph shows bilateral patchy pulmonary consolidations



**Figure 2.** Case 1 – (a) axial computed tomography scans of the abdomen and pelvis show right rectus abdominis muscle hematoma (b) extending into the extraperitoneal pelvis; (c) hemorrhagic collection posterior to the anterior abdominal wall



**Figure 3.** Case 2 – chest X-ray scan shows extensive bilateral pulmonary consolidations involving both lower lobes with a zone of reduced pericardial transparency of the left lung



**Figure 4.** Case 2 – (a) axial computed tomography scans of the abdomen and pelvis show bilateral rectus abdominis muscles hematomas (b) extending into the extraperitoneal pelvis; another hemorrhagic collection in the right retroperitoneum with displaced adjacent structures (c)